May 2026 Research Update

This month added a clearer picture that single-session Gamma Knife radiosurgery can keep many glomus jugulare tumors from growing and can keep symptoms from worsening for most people treated in one center. The same report also suggests that outcomes are not identical for everyone, with age and tumor stage relating to how well tumors stayed controlled. Side effects were reported as uncommon in this group, which is reassuring but still based on one center's experience. [1]

In 95 patients treated between 2010 and 2023, the study reported a tumor control rate of 96.9% and clinical control (symptoms not getting worse) of 93.9%. Younger age predicted worse tumor control, while a Glasscock-Jackson type 1 tumor predicted better prognosis. The authors also described a very low complication rate after Gamma Knife in this cohort. [1]

For patients and caregivers, this mainly adds confidence that radiosurgery is often followed by stable imaging and stable symptoms in real-world care, at least in the center that reported it. It also helps clarify that personal factors like age and tumor stage may relate to how durable control is, which may matter for expectations and follow-up planning. What remains uncertain is how closely these results match outcomes in other hospitals or in people with different tumor sizes and histories, because the report summarizes one center and does not compare directly with other treatments. [1]

This month, single-patient reports reminded readers that glomus jugulare tumors and related paragangliomas do not always announce themselves in typical ways. One case showed recurrence first appearing as facial nerve weakness, while another showed a tumor that secretly made stress hormones and caused a severe blood-pressure surge during embolization. These reports do not tell how often this happens, but they make the range of possible problems easier to picture. [2] [3]

In a 73-year-old woman with a distant history of glomus jugulare tumor, isolated facial nerve palsy was the first sign of recurrence. Because MRI could not be used due to metallic clips, CT imaging showed skull base involvement and PET DOTA-TATE supported the diagnosis; care included eye-protection surgery to prevent corneal damage while a skull-base team evaluated the tumor. This illustrates that new nerve symptoms can sometimes be a signal of return, and that alternative imaging may be used when MRI is not possible. [2]

In a 53-year-old woman with a large glomus jugulare tumor, a hypertensive crisis occurred during embolization and the tumor was later confirmed to be secreting catecholamines (stress hormones). After urgent surgical removal within 72 hours, hormone levels normalized and neurological symptoms improved, and there was no intraoperative blood-pressure crisis reported during the resection. This case highlights a rare but important safety issue during procedures for certain tumors, while also showing that the problem resolved after the tumor was removed in this patient. [3]

For patients, these reports mainly add awareness of two situations that may come up: recurrence that appears first as a new nerve problem, and a small subset of tumors that can release hormones that affect blood pressure during procedures. This does not change what is known for most people, because both are based on single patients and cannot show how common they are. What they do clarify is why teams may use different scans when MRI is not possible, and why careful planning around procedures can matter in unusual cases. [2] [3]

This month included an early look at what some head and neck paragangliomas may be doing at the cell level, using tumor staining tests. In three tympanic paragangliomas (a related tumor type near the ear), the tumors showed a pattern consistent with parts of catecholamine (stress-hormone) production, even though patients did not have obvious hyperadrenergic symptoms. The key message is that what a tumor can make in the lab does not always match what a person feels, and the clinical meaning is still uncertain. [4]

All three tumors showed strong staining for tyrosine hydroxylase and none stained for dopamine beta-hydroxylase, while one had focal staining for choline acetyltransferase. The tumors also showed moderate membranous SSTR2A staining, a receptor sometimes used for certain imaging approaches in this family of tumors. The authors called for more work to learn whether these tissue patterns relate to symptoms or risks in real life. [4]

For patients and caregivers, this is mainly early research that builds understanding rather than changing decisions right now. It helps explain why some paragangliomas might have the machinery to make stress hormones even when a person does not have classic symptoms, and why receptor staining may connect to specialized imaging in this tumor family. What remains unknown is whether these findings predict who will have hormone-related problems or different outcomes, since the report included only 3 tumors and did not link staining patterns to long-term clinical results. [4]